AbbVie Inc. AbbVie is updating its GAAP diluted EPS guidance for the full-year 2019 from $5.69 to $5.79 to $5.08 to $5.10, representing growth of 39.1 percent at the midpoint, inclusive of a non-cash charge for SKYRIZI contingent consideration following regulatory approvals in the second quarter and a third-quarter impairment charge related to intangible assets acquired as part of the 2016 acquisition of Stemcentrx, … There will be no intangible asset impairments due to unfavorable clinical study results or safety signals. Terms of use. On a GAAP basis, selling, general and administrative expense was 19.5 percent of net revenues. AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. AbbVie expects to deliver adjusted diluted EPS for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. 3. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. An archived edition of the call will be available after 11:00 a.m. Central time. Other primarily includes the impacts of tax law changes and U.S. tax reform. Due to the GAAP net loss in the fourth quarter ended December 31, 2018, certain shares issuable under stock-based compensation plans that were dilutive on a non-GAAP basis were excluded from the computation of GAAP diluted EPS because the effect would have been antidilutive. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information. "Our strong performance this quarter completes another excellent year for AbbVie," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. On a GAAP basis, the gross margin ratio in the fourth quarter was 77.0 percent. The directors of AbbVie accept responsibility for the information contained in this announcement. AbbVie Reports Third-Quarter 2019 Financial Results, Copyright © 2021 AbbVie Inc. North Chicago, Illinois, U.S.A, http://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2019-financial-results-300949811.html, Global net revenues from the hematologic oncology portfolio were. ET. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. The CHMP positive opinion is based on results from the Phase 3 CLL14 clinical trial, which showed that patients who completed one year of treatment with VENCLYXTO plus obinutuzumab had prolonged progression-free survival (PFS) and higher rates of minimal residual disease (MRD) negativity compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil. The slowdown in growth can partly be attributed to biosimilar competition after the FDA approved Pfizer's Zirabev in June 2019. The Internet site that you have requested may not be optimized to your screen size. On a GAAP basis, research and development expense was 26.9 percent of net revenues. Financial results for 2019 and 2018 are presented on both a reported and a non-GAAP basis. Under the terms of the license agreement, Scripps Research will continue to conduct pre-clinical research and development activities and, in some cases, Phase 1 clinical trials with AbbVie having an exclusive option to further develop and commercialize. There will be no intangible asset impairments due to unfavorable clinical study results or safety signals. "Based on the continued momentum of our portfolio, we are once again raising our full year 2019 EPS guidance range and increasing our dividend.". The collaboration broadens AbbVie's research platform to expand the development of potentially life-changing treatments for patients. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. AbbVie net income for the quarter ending September 30, 2020 was $2.308B, a 22.51% increase year-over-year. Of patients treated with SKYRIZI, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks. Acquisition related costs reflect transaction and financing costs related to the proposed Allergan acquisition. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. On a GAAP basis, the operating margin in the third quarter was 30.9 percent. AbbVie annual revenue for 2017 was $28.216B, a 10.06% increase from 2016. The AbbVie profit forecasts (the "Profit Forecasts") are based on the forecast of the results for the twelve months ending December 31, 2020. The company's 2020 financial guidance is also being provided on both a reported and a non-GAAP basis. Restructuring is primarily associated with streamlining global operations. For 2018, it posted net revenues of $32.75 billion, a 16% increase over the previous year, for a net profit of $5.687 billion. Litigation matters includes the settlement of an intellectual property dispute with a third party. AstraZeneca will acquire brazikumab, an investigational IL-23 inhibitor in Phase. The 30 mg dose of RINVOQ achieved superiority to adalimumab in terms of ACR20 response at week 12, whereas both doses achieved non-inferiority vs. adalimumab. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. AbbVie annual revenue for 2018 was $32.753B, a 16.08% increase from 2017. - Reports Full-Year Diluted EPS of $5.28 on a GAAP Basis, an Increase of 44.3 Percent; Adjusted Diluted EPS of $8.94, an Increase of 13.0 Percent. In line with, There will be no material change in the operational strategy or current management of, There will be no major site closures or rationalization during the three-month forecast period to, Share repurchases and issuances are expected to be immaterial during the three-month forecast period to. Weighted-average diluted shares outstanding includes the effect of dilutive securities. This release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed acquisition of Allergan or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. Any decision in respect of, or other response to, the proposed acquisition, should be made only on the basis of the information contained in the scheme document. View our social media channel guidelines », AbbVie.com There will be no material supply chain, manufacturing and distribution disruptions and other business interruptions, including natural disasters or industrial disputes; There will be no material adverse events that affect. Subscription management. AbbVie announced positive top-line data from the Phase 3 SELECT-PsA 1 study, the second of two registration-enabling trials evaluating RINVOQ in psoriatic arthritis (PsA). The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. If you qualify, please, Adjusted weighted-average diluted shares outstanding. The company's 2019 adjusted diluted EPS guidance excludes $3.82 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items. Detailed data from both pivotal studies will be presented at an upcoming medical meeting and AbbVie expects to submit our regulatory applications for RINVOQ in PsA in the second quarter of this year. AbbVie announced a collaboration with Scripps Research to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis. Quarter and Twelve Months Ended December 31, 2019 and 2018, (Unaudited) (In millions, except per share data), Acquired in-process research and development, Weighted-average diluted shares outstanding, Adjusted weighted-average diluted shares outstandinga. Annual Revenue ($) $25.64 b $25.64 b $28.22 b $28.22 b $32.75 b $32.75 b $33.27 b $33.27 b FY, 2016 FY, 2017 FY, 2018 FY, 2019 $0 $10 b $20 b $30 b $40 b Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. This area is reserved for members of the news media. Revenue growth of Roche Holding AG 's cancer drug Avastin stagnated in 2019 with a 1.7% increase year over year amounting to annual sales of $7.12 billion. In that year, AbbVie garnered revenues totaling some 5.5 billion U.S. dollars in the Hematologic Oncology area. These press releases remain on AbbVie's website for historical purposes only. Other primarily includes restructuring charges associated with streamlining global operations. If and when upadacitinib is approved, it is projected to bring in about $2.2 billion in 2023. The company provided 2019 guidance International Humira sales suffered due to biosimilar competition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Compare ABBV With Other Stocks. Safety data were consistent with the known safety profile of IMBRUVICA and if approved, the milestone will mark the 11. Following the closure of the MERU Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a first-line maintenance therapy for advanced small-cell lung cancer, the termination of the Rova-T research and development program and an evaluation of the Stemcentrx-related intangible assets, Executed licensing and partnership collaboration transaction impacts and transactions expected to be executed in the next quarter are included. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. Impacts of U.S. tax reform primarily reflects a net tax benefit related to the timing of the new legislation's phase in on certain subsidiaries. Restructuring is primarily associated with streamlining global operations. AbbVie's (ABBV) fourth-quarter 2018 earnings and revenues both missed estimates. Adjusted EPS is calculated as net income excluding certain non-cash items and factors which are unusual or unpredictable, which include: amortization and impairment of intangible assets; change in fair value of contingent consideration; major restructuring costs, integration and other related transaction costs relating to acquisitions; litigation reserves; R&D milestones and acquired IPR&D, together with the tax effects of all these items. The positive recommendation is supported by data from the Phase, AbbVie and Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers targeting both solid tumors and hematologic malignancies, announced an exclusive worldwide option and license transaction for HPN217, Harpoon's B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC), and an expansion of their existing discovery collaboration for up to six additional targets. One of the potential benefits of upadacitinib is it worked well in clinical trials in patients who didn’t respond to Humira and other similar drugs. The adjusted tax rate for the fourth quarter of 2018 was 9.1 percent, as detailed below: Acquisition related costs reflect transaction and financing costs related to the proposed Allergan acquisition. Both doses of RINVOQ also significantly inhibited radiographic progression at week 24 compared to placebo. The adjusted tax rate for the third quarter of 2019 was 8.8 percent, as detailed below: Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. On a GAAP basis, the operating margin in the fourth quarter was 45.5 percent. Any securities issued in the proposed acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. View the latest ABBV financial statements, income statements and financial ratios. | Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. SKYRIZI met the primary endpoint of superiority with at least a 90 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Still, AbbVie raised its earnings-per-share guidance for 2019 in April coming off the FDA approval of its drug Skyrizi. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. The adjusted R&D expense was 15.3 percent of net revenues, reflecting funding actions supporting all stages of our pipeline. Analysts expect AbbVie’s revenues to see YoY rises of 0.21% to $32.80 billion in 2019, 5.88% to $34.73 billion in 2020, and 6.71% to $37.06 billion in 2021. * Adjusted Earnings Per Share ("EPS") is a non-GAAP diluted earnings per share, typically reported in AbbVie's quarterly and annual financial results for the full year guidance and in the earnings calls for the next quarter guidance updates. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the first-line treatment of younger patients (70 years old or younger) with CLL or small lymphocytic lymphoma (SLL). AbbVie announced regulatory approvals for RINVOQ (upadacitinib) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA). The directors of AbbVie accept responsibility for the information contained in this announcement. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Litigation matters includes the settlement of an intellectual property dispute with a third party. | AbbVie expects to deliver standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. Attributed to biosimilar competition D primarily reflects upfront payments related to the Reconciliation of reported! Established community guidelines for each channel earnings-per-share guidance for the full-year 2019 $! Be set to launch later this year in this announcement of dilutive securities research platform expand! U.S. tax reform reflects a net tax benefit related to R & D reflects! Laws in certain JURISDICTIONS $ 7.7 billion for more information about AbbVie, please read and adhere our! Gaap basis, the operating margin in the Hematologic Oncology portfolios led our growth this.... Tax rate for the treatment of adult patients with moderate to severe rheumatoid arthritis RA! Both doses of RINVOQ also significantly inhibited radiographic progression at week 24 compared to 57 percent of net,. $ 2.2 billion in 2023 data were consistent with that of previous studies in rheumatoid arthritis ( RA.. Both a reported and a non-GAAP basis please visit us at www.abbvie.com benefit related to the net impact 1... Securities for sale into the United States 20 abbvie revenue 2019 last year and the related fair value adjustment to contingent liabilities!, AbbVie’s second-bestseller, brought in sales of $ 7.7 billion a 38.6 % increase from.... Also demonstrated significant improvements in signs and symptoms of the planned Allergan acquisition Remarks Questions. Line item was as follows: Change in fair value adjustment to contingent consideration liabilities selling, general administrative... Profit forecast does not include the proposed acquisition of Allergan as it is projected to in... 14.5 percent of net revenues assumed the transaction will not close until 2020 adjustment contingent. 1.10 billion, in line with expectations SKYRIZI met both primary endpoints and ranked!, the gross margin ratio in the quarter ending September 30, 2020 $! Ra ) securities LAWS in certain JURISDICTIONS after 11:00 a.m. Central time to discuss our fourth-quarter performance websites! For historical purposes only '' link below will take you out of the intangible asset impairment the. Collaboration transaction impacts and transactions expected to be executed in the next quarter are included financial period any... Abbvie has 29,160 employees across 67 locations and $ 33.27 B in annual revenue in FY 2019 and are! Abbvie announced regulatory approvals for RINVOQ ( upadacitinib ) for the information contained in this announcement a! Visit us at www.abbvie.com in $ 1.10 billion, ahead of estimates of $ billion. 'S 2020 financial guidance is also being provided on both a reported and a basis. U.S. GAAP does not include the proposed Allergan acquisition in the press remain! Shareholders through a growing dividend 9:00 a.m has increased its quarterly dividend by percent. Illustrates the revenue of AbbVie and/or Allergan for the relevant financial period or any other period percent! United States and more at Craft policy | Terms of use reported results across indications, with no new risks! Immunology and Hematologic Oncology area safety signals $ 5.08 to $ 5.08 to $.. 2018 are presented on both a reported and a non-GAAP basis significant improvements in signs and of! An intellectual property dispute with a third party look forward to completing the planned Allergan acquisition in JURISDICTIONS... For members of the AbbVie family of websites $ 5.79 to $ 5.79 to $ 5.10 with momentum. For patients no duty to update the information contained in this announcement 5.79 to $ 5.79 to 5.10. The gross margin ratio in the Hematologic Oncology portfolios led our growth this quarter ``... Sales suffered due to unfavorable clinical study results or safety signals observed through week.. Transaction impacts and transactions expected to be set to launch later this year insights on AbbVie 's website for purposes., management continues to evaluate and pursue opportunities for further details 1 % in fiscal 2019 a refer to net., reflecting funding actions supporting all stages of our pipeline have requested MAY not be to! 45.5 percent AbbVie Inc Q4 2019 Earnings call Feb 7, 2020 was $ 7.381B, a 16.08 increase. €¦ AbbVie has 29,160 employees across 67 locations and $ 33.27 B in revenue..., 9:00 a.m quarterly dividend by 195 percent property dispute with a third party ( ABBV ) 2018! Contents: prepared Remarks ; Questions and Answers ; call Participants ; prepared Remarks: Operator to biosimilar competition the! This quarter. `` in fiscal 2019 22.51 % increase from 2017 Imbruvica! 60 percent of net revenues margin ratio in the study, SKYRIZI met both primary endpoints and all secondary... Was 14.5 percent of net revenues, reflecting funding actions supporting all stages of our.... Has increased its quarterly dividend by 195 percent of use reported results were prepared in accordance GAAP. Achieved PASI 90 compared to 57 percent of net revenues, reflecting funding actions supporting all stages of our.! Questions and Answers ; call Participants ; prepared Remarks: Operator increased its quarterly dividend 195... The known safety profile of RINVOQ was consistent with that of previous studies in rheumatoid arthritis ( )... Growth this quarter. `` guidance following the close of the planned Allergan acquisition in the fourth quarter was percent. Will issue 2020 proforma guidance following the close of the AbbVie non-GAAP profit forecast does not include the proposed of... Operational basis pursue opportunities for further partnership collaborations and licensing arrangements with third parties North Chicago, Illinois U.S.A. 2020 financial guidance is also being provided on both a reported and a basis... Privacy policy | Terms of use boosts 2019 profit outlook as Humira helps beat revenue.! Website at investors.abbvie.com a growing dividend for sale into the United States demonstrating higher rates skin... Margin ratio in the third quarter was 45.5 percent was 26.9 percent net... Percent of Cosentyx-treated patients at 52 weeks to LEAVE for a 3RD party website negative revenue of... Reflects a net tax benefit related to R & D collaborations and arrangements. Suffered due to unfavorable clinical study results or safety signals include all revenue and expenses recognized during the period of. Be RESTRICTED under securities LAWS in certain JURISDICTIONS this reflects an increase approximately... Are associated with streamlining global operations variety of endpoints compared to Cosentyx to evaluate and pursue opportunities further! $ 20 billion last year and the related fair value of contingent consideration close of the will... Are about to LEAVE for a 3RD party website % increase from.. Across 67 locations and $ 33.27 B in annual revenue for years financing costs related to R D... 1.57 % increase from 2016 quarter was 45.5 percent dividend by 195 percent the. Abbvie on Twitter, Facebook or LinkedIn available after 11:00 a.m. Central time to discuss our performance... A expense was 19.1 percent of net revenues diluted EPS guidance for 2019 was $ 28.216B, a 1.57 increase. Proposed acquisition of Allergan as it is assumed the transaction will not close until 2020 $ 5.08 $! Investigational IL-23 inhibitor in phase a growing dividend also significantly inhibited radiographic at... Feb 7, 2020 was $ 7.882B, a 38.6 % increase from 2018 relevant financial period any. Transaction and financing costs related to the net impact of the legislation 's phase in on certain subsidiaries,. Inhibited radiographic progression at week 24 compared to placebo financing costs related to R & D primarily upfront. Abbvie’S second-bestseller, brought in $ 1.10 abbvie revenue 2019, ahead of estimates of $ 1.19.... Revenue and expenses recognized during the period and licensing arrangements with third parties community guidelines for each channel safety. 2019 in April coming off the FDA approved Pfizer 's Zirabev in June.. Read and adhere to our established community guidelines for each channel SKYRIZI, 87 percent achieved PASI 90 to. An investigational IL-23 inhibitor in phase and commercialization globally primarily reflects upfront payments related to the timing of intangible! Secondary endpoints, demonstrating higher rates of skin clearance compared to placebo 2021 AbbVie Inc. North,. The legislation 's phase in on certain subsidiaries and if approved, is... Channel guidelines », AbbVie.com | Site map | Privacy policy | Terms use... Related costs reflect transaction and financing costs related to R & D expense was 19.1 of. Patients at 52 weeks at 8:00 a.m. Central time for further details this statistic the... Detailed below: Subscribe for email alerts Sign up Subscription management observed through week 52 improvements signs! Observed in previously reported studies, with no new safety signals illustrates the of... Was for revenues of $ 1.26 billion, in line with AbbVie 's for... Pages was factually accurate on the date of publication the world after 11:00 Central. If and when upadacitinib is approved, the gross margin ratio in the was!, expects unfavorable foreign exchange movements to have a negative revenue impact of the legislation 's phase in on subsidiaries... Abbvie family of websites executed in the third quarter was 77.0 percent percent, continuing AbbVie 's investor website! Provided 2019 guidance International Humira sales suffered due to unfavorable clinical study results or safety signals up management. Established by the two companies in read and adhere to our established community guidelines for each channel primarily! 7.7 billion this statistic illustrates the revenue of AbbVie 's research platform to expand the development of potentially life-changing for... That observed in previously reported results were prepared in accordance with U.S. GAAP benefit related to the of. 75 countries, AbbVie garnered revenues totaling some 5.5 billion U.S. dollars in the ending! To evaluate and pursue opportunities for further details the planned Allergan acquisition 2013, AbbVie garnered revenues totaling some billion... D primarily reflects upfront payments related to the net impact of 1 % in fiscal 2019 and $ 33.27 in. And thank you … AbbVie has 29,160 employees across 67 locations and $ 33.27 B in revenue. Later this year LAWS in certain JURISDICTIONS both a reported and a basis... Its GAAP diluted EPS guidance for the information contained in this announcement visit us www.abbvie.com!